- Home
- MDGL
as 11-20-2024 4:00pm EST
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 7.4B | IPO Year: | N/A |
| Target Price: | $347.33 | AVG Volume (30 days): | 654.8K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -25.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $168.25 - $368.29 | Next Earning Date: | 10-31-2024 |
| Revenue: | $76,813,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 193.46% |
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Levy Richard S | MDGL | Director | Nov 7 '24 | Sell | $350.00 | 5,000 | $1,750,000.00 | 11,012 | |
| Levy Richard S | MDGL | Director | Nov 1 '24 | Sell | $301.96 | 5,000 | $1,504,703.41 | 11,012 | |
| Sibold William John | MDGL | President and CEO | Sep 9 '24 | Sell | $243.83 | 6,363 | $1,551,490.29 | 55,887 |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
Pharma Voice
3 days ago
The first MASH drug could open the door for others — including GLP-1s
GuruFocus.com
6 days ago
John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC
Zacks
10 days ago
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Motley Fool
11 days ago
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
Zacks
13 days ago
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Simply Wall St.
14 days ago
3 High Growth Tech Stocks Leading The US Market
GlobeNewswire
15 days ago
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
MT Newswires
15 days ago
Madrigal Pharmaceuticals Insider Sold Shares Worth $1,504,703, According to a Recent SEC Filing
Compare MDGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.